Further studies are needed to demonstrate that monitoring HMGB1/sRAGE, together with other prognostic parameters, may be a useful tool to evaluate the risk stratification of clinical manifestation(s) during APS. The gene discussed is HMGB1; the disease is autoimmune polyendocrinopathy.